Boehringer Ingelheim and Sosei Sign Potential $732 Million Collaboration for Schizophrenia Treatment

1. Boehringer Ingelheim has initiated a collaboration with Sosei to develop novel therapies targeting schizophrenia through a potential $732 million deal.
2. As part of this agreement, Boehringer Ingelheim made an initial payment of $27.3 million to Sosei.
3. The focus of the partnership is on Sosei's portfolio targeting gamma-aminobutyric acid receptor subtype 52 (GPR52).
4. This new partnership aims to advance the development of innovative schizophrenia treatments.